Tuesday, February 19, 2013    |    
BIO-IT World    |    Archives    |    Advertising   |    CHI Conferences    |    Subscribe 



DREAM Project and Sage Bionetworks Join Forces
Bio-IT World | Sage Bionetworks and the DREAM Project— Dialogue on Reverse Engineering Assessment and Methods—are merging efforts to run open science computational challenges which foster the broader collaboration of the research community and provide a meaningful impact to both discovery and clinical research. Read More

Ion Torrent Edges Illumina in Sales Battle of Benchtop Sequencers, Says Macquarie Report
Bio-IT World | Sales of the Ion Torrent desktop sequencers exceed those of its rival MiSeq machine from Illumina, according to a new report from Macquarie Equities Research, which highlights encouraging trends for both Illumina and Ion Torrent parent company, Life Technologies. Read More

PeerJ Rolls Out New Open Access Journal, Platform
Bio-IT World Roundup | This week, PeerJ published its first articles--on sauropod necks, the cups and balls trick, anti-apoptotic signaling in mammalian hibernation and more. The scientific publishing site is more than just an open access publisher. PeerJ has built an innovative platform from scratch. Read More

sbv IMPROVER Launches Species Translation Challenge
Bio-IT World | sbv IMPROVER announced its next challenge today at the Molecular Medicine Tri-Conference in San Francisco. The Species Translation Challenge is an open scientific challenge that will use crowdsourcing to help define the limits of rodent models as predictors of human biology. The challenge will launch later in 2013. Read More

Cancer Commons Expands Pre-Competitive Alliance
Bio-IT World | Cancer Commons has announced six new cancer ecosystem Alliance members: Knight Diagnostic Laboratories at Oregon Health & Science University (OHSU); the Thoracic Oncology Program, University of Chicago Medicine; Science Exchange, an online marketplace for scientific services; and patient advocates the Bonnie J. Addario Lung Cancer Foundation, Imerman Angels, and Melanoma Research Foundation. Read More

Nominations Open For 2013 Franklin Award
Bio-IT World | Bioinformatics.org is accepting nominations now for the 2013 Benjamin Franklin Award for Open Access in the Life Sciences. The award is a humanitarian/bioethics award presented annually to an individual who has, in his or her practice, promoted free and open access to the materials and methods used in the life sciences. Nominations are being accepted until Monday, February 18. Read More

Strand Gets Burrill Seal of Approval
Bio-IT World | Strand Life Sciences is no biotech newcomer, but the Bangalore, India-based company is getting a burst of new attention after San Francisco-based Burrill & Company today announced a multi-million dollar investment in the company. The new funds will be used to accelerate the growth of the company's evolution into precision diagnostics in health care and expand Strand's reach into global markets, the company says. Read More


The Staffing Contradictions in Biotech
Xconomy | After layoffs in the 150,000 range from 2009-2012, pharma and biotech are lamenting their lack of qualified workers to grow their businesses. Read More

AWS Data Warehouse Now Available
Computerworld | Amazon Web Services has released its cloud-based data warehouse Redshift to all users. Redshift users can provison a single 2TB data warehouse or as a cluster of 16 2TB nodes or 16TB nodes, by default. Read More

The Genomics Tipping Point
Wired | Genomics is poised for a "cell phone moment," Wired says--the tipping point where the technology becomes a commodity, hardware is cheap, and software and apps drives the industry. Read More

Latest Look at BGI
Technology Review | Behind the doors in Shenzhen, 1,000 bioinformaticians are working on 2,000 human genomes, 90 varietys of chickpea, and a host of other grand projects. Read More

Sanofi Buys More Regeneron Biotech Stocks
Reuters | Sanofi is buying more shares of Regeneron Pharmaceuticals, its current partner on cholesterol and rheumatoid arthritis. Sanofi currently controls 16.7% of the company but has the right to control up to 30%. Read More